Literature reports indicate that genetic variants, primarily in the enzymes thiopurine S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15), are associated with an increased risk of developing myelosuppression, conferring up to twice the risk [5]. This evidence concerns the gene NUDT15 and myelosuppression.